We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Labelled compounds as radiopharmaceuticals for radiosynoviorthesis.
- Authors
Melichar, F.; Kropacek, M.; Srank, J.; Beran, M.; Mirzajevova, M.; Zimova, J.; Eigner-Henke, K.; Forsterova, M.
- Abstract
Radiopharmaceuticals for radiosynoviorthesis are designed as suspension (colloidal) of particles in sterile and pyrogen free form, where radionuclide (active substance) fix on carrier which is form solid particles or gel form. Generally, radionuclide and carrier have to fulfil the request of sterility, chemical purity, non toxicity, non allergen and low cost preparation. In term of the radionuclide purity, beta-emission with sufficient energy for penetration and ablation the synovial tissue and low gamma-radiation is requested. The radionuclide gold-198 in colloidal form was used as radiopharmaceutical for radiosynoviorthesis at first. Presently, beta-emitting radionuclides, which have no or only a minimal gammaemission, are used. Between such radionuclides is possible to insert: yttrium-90, rhenium-186 and radiolanthanoides — dysprosium-165, holmium-166 and erbium-169. In this paper are presented experiences with preparation [166Ho] Holmium-Macroaggregates ([166Ho] holmium-MA), [166Ho] holmium-Polylactic Acid Microspheres ([166Ho] Ho-PLA-MS) which are potential candidate for radiosynoviorhesis.
- Subjects
RADIOPHARMACEUTICALS; RADIOISOTOPES; SUSPENSIONS (Chemistry); GAMMA rays; RADIOCHEMISTRY; YTTRIUM; RHENIUM
- Publication
Journal of Radioanalytical & Nuclear Chemistry, 2009, Vol 280, Issue 2, p353
- ISSN
0236-5731
- Publication type
Article
- DOI
10.1007/s10967-009-0526-4